AyurMaya: Funding, Team & Investors | Startup Intros

Loading organizations...

AyurMaya: Funding, Team & Investors | Startup Intros

Financial History

Total Raised

N/A

Valuation

N/A

Investments Made

Date	Company	Round	Lead Investor(s)	Co-Investor(s)
Apr 1, 2024	Endeavor BioMedicines	$130.0M Series C	AyurMaya, Karan Takhar	Atlas Venture, Hatteras Venture Partners, Omega Funds, RA Capital, Roche Venture Fund, abrdn, Ally Bridge Group, Avidity Partners, Eckuity Capital, Fidelity Management & Research Company, Invus, Longitude Capital, Perceptive Advisors, Piper Heartland Healthcare Capital, Silver Arch Bio, SymBiosis, T. Rowe Price Associates, Velosity Capital, Woodline Partners
Mar 1, 2024	Alumis	$260.0M Series C	Foresite Capital, Srinivas Akkaraju	ARCH Venture Partners, Atlas Venture, Deerfield Management, F-Prime Capital Partners, The Column Group, venBio, Ally Bridge Group, Cormorant Asset Management, HBM Healthcare Investments, Lilly Asia Ventures, Nextech, Omega Funds, Piper Heartland Healthcare Capital, SR One
Sep 1, 2023	ReCode Therapeutics	$50.0M Series B	—	Bioluminescence Ventures, InterWest, Intuitive Ventures, MPM Capital, OrbiMed, Pfizer Venture Investments, Polaris Partners, Vida Ventures, Sam Altman, Amgen Ventures, EcoR1 Capital, Leaps by Bayer, Osage University Partners, Sanofi Ventures, Solasta Ventures
May 1, 2023	ElevateBio	$400.0M Series D	AyurMaya, Matrix Capital Management	MPM Capital, RA Capital, EcoR1 Capital, EDBI, Emerson Collective, F2 Ventures, Fidelity Management & Research Company, Khalil Barrage, Lee Family Office, Karina Thorn, R&D partner, Redmile Group, Samsara BioCapital, SoftBank, Surveyor Capital, Vertex Ventures, Woodline Partners
Sep 1, 2022	ACELYRIN	$300.0M Series C	Access Biotechnology	Atlas Venture, Contrary Capital, Mott Family Capital, Matthew McAviney, Robert Garland, venBio, Westlake Village BioPartners, Ron Pragides, Cowen Healthcare Investments, Decheng Capital, Marshall Wace, OrbiMed, Samsara BioCapital, Surveyor Capital, Tybourne Capital Management
Jun 29, 2022	ReCode Therapeutics	$120.0M Series B Extension	Alan Colowick, Juergen Eckhardt	Amgen Ventures